Pneumonia Drug Developer Nabriva Eyes $92M IPO
Nabriva Therapeutics AG, a venture capital-backed Austrian life sciences company focused on developing a pneumonia treatment, filed Thursday to raise up to $92 million in a U.S. initial public offering guided...To view the full article, register now.
Already a subscriber? Click here to view full article